Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide, which is increasing particularly among females. Smoking represents the main risk factor for developing COPD; however, the chronic inflammation persists following smoking cessation. A plethora of inflammatory mediators are likely to orchestrate this persistent inflammation with resulting tissue remodeling and decline in lung function. We have investigated the effects of smoking, in relation to disease, on oxylipins as key lipid mediators in the inflammatory response in the lower airways.
Rationale:
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide, which is increasing particularly among females. Smoking represents the main risk factor for developing COPD; however, the chronic inflammation persists following smoking cessation. A plethora of inflammatory mediators are likely to orchestrate this persistent inflammation with resulting tissue remodeling and decline in lung function. We have investigated the effects of smoking, in relation to disease, on oxylipins as key lipid mediators in the inflammatory response in the lower airways.
Methods:
Bronchoalveolar lavage fluid (BALF) was obtained from healthy never-smokers, non-symptomatic smokers, and COPD patients of GOLD stage I-II (smokers and ex-smokers) of both genders (20 per group, n=120). Eighty-five different lipid mediators derived from the cytochrome P450 (CYP), lipoxygenase (LOX) and cyclooxygenase (COX) pathways were simultaneously analyzed by off-line solid phase extraction followed by ultraperformance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS).
Results:
Thirty-five lipid mediators were detected in >50% of the samples. Data were analyzed by principal component analysis (PCA , R 2 =0.608 Q 2 =0.498), with partial separation observed between smokers and non-smokers (Figure 1 .B). Products of 12/15-LOX (n=9) and 5-LOX (n=5) clustered in the loadings plot (Figure 1.A) . Therefore, all quantified products of theses enzymes were summed for further statistical comparisons. The sum of 12/15-LOX products showed gender-specific behavior in the disease path, but only two comparisons were significant: male vs. female healthy nonsmokers and non-smoker vs. smoker healthy males. A different trend was observed for 5-LOX products with male and female healthy non-smokers showing lower levels of 5-LOX products compared, respectively, to male and female healthy smokers. There were no difference in 5-LOX levels between smokers and smoking COPD patients. However, in COPD ex-smokers the levels of 5-LOX products were decreased compared to COPD smokers.(significant for females, but not for males; posteriori P 0.11).
Discussion
Lipoxygenase activity in BALF shows gender-specific regulation in relation to both smoking and disease. The observed shifts were 5-LOX-and 15-LOX-specific, with smoking in both genders driving changes in 5-LOX activity whereas 12/15-LOX showed gender-specific regulation in COPD. These findings suggest that distinct lipid mediator biosynthetic pathways evidence unique responses to both disease and smoking. The observed gender-specific component provides potential insight into the gender imbalance in COPD cases and warrants further investigation. 
